How pharma should prep for the six-bill avalanche from Congress

The bipartisan legislative push could create big hurdles for drug development, with concerns mounting over limited patent protections and increased litigation risks, hears Marisa Woutersen.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

USPTO speeds up patent issuance amid widespread agency changes

17 April 2025 Prompter patent issue will provide earlier protection for inventions and could avoid need for Quick Path Information Disclosure Statements, says USPTO.

Big Pharma

AstraZeneca fends off diabetes generic, for now

10 April 2025 Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC.

More on this story

Americas

USPTO speeds up patent issuance amid widespread agency changes

17 April 2025 Prompter patent issue will provide earlier protection for inventions and could avoid need for Quick Path Information Disclosure Statements, says USPTO.

Big Pharma

AstraZeneca fends off diabetes generic, for now

More on this story

Americas

USPTO speeds up patent issuance amid widespread agency changes

17 April 2025 Prompter patent issue will provide earlier protection for inventions and could avoid need for Quick Path Information Disclosure Statements, says USPTO.

Big Pharma

AstraZeneca fends off diabetes generic, for now